Cronos Group Inc (NASDAQ:CRON) shares gapped down before the market opened on Friday . The stock had previously closed at $8.38, but opened at $8.94. Cronos Group shares last traded at $8.83, with a volume of 153143 shares.
Several brokerages have recently weighed in on CRON. Canaccord Genuity upgraded shares of Cronos Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 15th. Zacks Investment Research upgraded shares of Cronos Group from a “hold” rating to a “buy” rating and set a $9.25 price objective on the stock in a report on Tuesday. Finally, Cann started coverage on shares of Cronos Group in a report on Friday, October 12th. They set a “sell” rating and a $4.50 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $6.88.
The company has a current ratio of 52.98, a quick ratio of 44.71 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.60 billion and a P/E ratio of 855.00.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC purchased a new position in Cronos Group in the third quarter valued at approximately $111,000. Tower Research Capital LLC TRC raised its holdings in Cronos Group by 10,393.4% in the second quarter. Tower Research Capital LLC TRC now owns 17,419 shares of the company’s stock valued at $114,000 after buying an additional 17,253 shares during the period. Stratos Wealth Partners LTD. purchased a new position in Cronos Group in the third quarter valued at approximately $116,000. Oppenheimer & Co. Inc. purchased a new position in Cronos Group in the third quarter valued at approximately $121,000. Finally, Exane Derivatives purchased a new position in Cronos Group in the third quarter valued at approximately $123,000. Hedge funds and other institutional investors own 9.77% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Cronos Group (CRON) Shares Gap Down to $8.94” was first reported by Macon Daily and is the property of of Macon Daily. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://macondaily.com/2018/11/09/cronos-group-cron-shares-gap-down-to-8-94.html.
About Cronos Group (NASDAQ:CRON)
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada.
See Also: Outstanding Shares
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.